Equity Profile

ABT

Abbott Laboratories

Health CareHealth Care Equipment$160.4B

Jul16Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Abbott Laboratories (ABT) is a global health care company that develops and manufactures a wide range of medical devices, diagnostics, and nutritional products. With a market cap of $160 billion, it plays a crucial role in health care equipment, focusing on innovation and improving patient outcomes.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

$1.28

Revenue

Revenue growth reflects the company's ability to sell its products and expand its market presence.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1-2026, Abbott reported an EPS of $1.15, slightly beating estimates. However, the stock dropped 6% the following day, indicating market skepticism despite the positive surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Abbott to report solid earnings with an EPS of $1.28 and revenue of $12.5 billion. The market is closely watching for any signs of growth in key product lines.

Bull Case

If Abbott exceeds expectations, it could signal strong demand for its products, leading to a positive stock reaction and renewed investor confidence.

Bear Case

Conversely, if Abbott fails to meet earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and lead to a significant stock decline.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.28

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$12.5B

Revenue growth reflects the company's ability to sell its products and expand its market presence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's revenue growth meet or exceed the $12.5 billion consensus?

Revenue performance is critical for assessing the company's market position and growth potential, especially in a competitive landscape.

What commentary will management provide regarding future product demand?

Insights into product demand will help investors understand Abbott's growth prospects and any potential challenges ahead.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Abbott's ability to drive revenue growth due to recent product innovations that have not been fully reflected in analyst models.

Supporting Evidence

The options market is pricing in an 8.67% move, indicating expectations of significant volatility that may not align with historical performance.

Abbott has consistently beaten EPS estimates, suggesting that analysts may be conservative in their projections.

Key Risk

If revenue growth exceeds $12.5 billion, it could challenge the current bearish sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on Abbott's ability to sustain growth in a challenging economic environment, with particular attention to revenue and product demand.

Bull Confirmed If

Reporting revenue growth above $12.5 billion would confirm strong market demand and investor confidence.

Bear Confirmed If

Falling short of the $1.28 EPS target could signal deeper issues within the company's operations.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by around 4.62% on the first day, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may experience a muted reaction as investors reassess growth prospects.

Miss

A miss on earnings could lead to a decline of around 3.34%, as investors react negatively to potential weaknesses in the business.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·1 sell

Members

House only

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-GARichard Dean Dr McCormickRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's insights on market trends and competitive positioning.
3Details on cost management strategies and their effect on margins.
4Comments on international sales performance and growth opportunities.
5Any guidance on future earnings expectations and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

$1.28

Revenue

Revenue growth reflects the company's ability to sell its products and expand its market presence.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1-2026, Abbott reported an EPS of $1.15, slightly beating estimates. However, the stock dropped 6% the following day, indicating market skepticism despite the positive surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Abbott to report solid earnings with an EPS of $1.28 and revenue of $12.5 billion. The market is closely watching for any signs of growth in key product lines.

Bull Case

If Abbott exceeds expectations, it could signal strong demand for its products, leading to a positive stock reaction and renewed investor confidence.

Bear Case

Conversely, if Abbott fails to meet earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and lead to a significant stock decline.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.28

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$12.5B

Revenue growth reflects the company's ability to sell its products and expand its market presence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's revenue growth meet or exceed the $12.5 billion consensus?

Revenue performance is critical for assessing the company's market position and growth potential, especially in a competitive landscape.

What commentary will management provide regarding future product demand?

Insights into product demand will help investors understand Abbott's growth prospects and any potential challenges ahead.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Abbott's ability to drive revenue growth due to recent product innovations that have not been fully reflected in analyst models.

Supporting Evidence

The options market is pricing in an 8.67% move, indicating expectations of significant volatility that may not align with historical performance.

Abbott has consistently beaten EPS estimates, suggesting that analysts may be conservative in their projections.

Key Risk

If revenue growth exceeds $12.5 billion, it could challenge the current bearish sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on Abbott's ability to sustain growth in a challenging economic environment, with particular attention to revenue and product demand.

Bull Confirmed If

Reporting revenue growth above $12.5 billion would confirm strong market demand and investor confidence.

Bear Confirmed If

Falling short of the $1.28 EPS target could signal deeper issues within the company's operations.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by around 4.62% on the first day, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may experience a muted reaction as investors reassess growth prospects.

Miss

A miss on earnings could lead to a decline of around 3.34%, as investors react negatively to potential weaknesses in the business.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·1 sell

Members

House only

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-GARichard Dean Dr McCormickRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's insights on market trends and competitive positioning.
3Details on cost management strategies and their effect on margins.
4Comments on international sales performance and growth opportunities.
5Any guidance on future earnings expectations and market conditions.